Color-Coded Microspheres Make Vessel Embolization Easier

Syringes that are pre-filled with a range of color-coded embolization microspheres enable physicians to accurately perform blood vessel occlusions.

The Embozene Color-Advanced microspheres are intended for treatment of hyper-vascularized tumors such as uterine fibroids, ArterioVenous Malformations (AVMs), hepatocellular carcinomas (HCCs), and other highly vascularized cancers. The microspheres consist of a hydrogel core and an exterior shell made from Polyzene-F (poly[bis(trifluroexthoxy)phosphazene]), and are color- enhanced with a different color for each size for increased procedural safety, efficiency, and visibility. The microspheres are available in 40 micrometers, 100 micrometers, 250 micrometers, 400 micrometers, 500 micrometers, 700 micrometers, and 900 micrometers sizes, in both 1 ml and 2 ml pre-filled syringes and vials. The microspheres are precisely calibrated and retain their shape after passing through a catheter, allowing them to stay in the delivery suspension for an extended period.

The color-coding improves particle visibility, increases procedural safety, and optimizes handling and convenience for the physician. Instant visual confirmation of the microsphere size eliminates potential waste due to size uncertainty, when operating with multiple microsphere sizes. Using different containers prevents contamination of saline and contrast syringes during the procedure. The increased visibility allows confirmation of microsphere levels in the suspension prior to and during injection, and reduces the risk of injecting too many or very few particles because the microspheres are visible, especially when using smaller sizes. The Embozene Color-Advanced microspheres are a product of CeloNova BioSciences (Newnan, GA, USA), and have been approved by both the U.S. Food and Drug Administration (FDA) and the European Community (CE Marking).

"From the outset, we took a different approach to developing our Embozene Microspheres by asking physicians and medical scientists for the qualities and characteristics that the ideal embolic device should have,” said Thomas A. Gordy, President and CEO of CeloNova BioSciences. "Then we engineered Embozene Microspheres to have those properties, which are made even better with Polyzene-F, our proprietary polymer.”

Related Links:
CeloNova BioSciences